🔎 Trials Near Me

Akèy › Kansè san › Oklahoma › Oklahoma City

Etid klinik pou Kansè san nan Oklahoma City, OK

7 etid pou Kansè san ap chèche patisipan nan sit nan ak bò kote Oklahoma City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

Ap rekriteEtid obsèvasyon
  • Mercy Hospital Oklahoma City, Oklahoma City
Tout laj · Tout sèks · Mizajou Oct 5, 2026 · NCT04242095

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • Mercy Hospital Oklahoma City, Oklahoma City
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Ap rekriteFaz 1
  • OU Health Stephenson Cancer Center, Oklahoma City
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06001788

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

Ap rekriteFaz 2
  • OU Health Physicians - Infectious Disease Clinic, Oklahoma City
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT06665100

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Ap rekriteEtid obsèvasyon
  • University of Oklahoma Health Science Center, Oklahoma City
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

Ap rekriteFaz 3
  • University of Oklahoma Health Sciences Center, Oklahoma City
Laj 2 a 18 · Tout sèks · Mizajou May 5, 2026 · NCT05711667

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Ap rekriteFaz 1
  • OU Health Stephenson Cancer Center, Oklahoma City
Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT05735184

Etid Kansè san nan lòt vil

Lòt etid nan Oklahoma City

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.